Drug Topics
NOVEMBER 19, 2024
Investigators said there is an imperative to optimize medication utilization and explore the consequences of medication burden on treatment outcomes in patients with long COVID.
STAT
NOVEMBER 20, 2024
Tonya Brand was horrified to find a piece of metal poking out of her inner thigh while relaxing at her house in Georgia in 2011. She had no idea what it could be. It was only after extensive imaging that her doctors realized what had happened: A medical device that had been implanted in her two years earlier to catch blood clots had broken and was now migrating to different parts of her body.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
NOVEMBER 19, 2024
More than half of health system and health plan executives say AI is an immediate priority, and 73% are increasing their investments in the technology, a new C-suite survey finds. | More than half of health system and health plan executives say AI is an immediate priority, and 73% are increasing their investments in the technology, a new C-suite survey finds.
STAT
NOVEMBER 19, 2024
When Makena, a drug designed to prevent preterm births, hit the market in 2011 at $1,500 per dose, it drew rife backlash. The drug was based on an active ingredient that had been available for many years at a much lower cost. Confronted with the public outcry, the FDA took an unusual step: It allowed pharmacies to continue making their own copies of the drug through the practice of pharmacy compounding, selling it at a fraction of Makena’s price.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
NOVEMBER 18, 2024
The disorder presents as severe lung disease, with lung transplantation as the only current therapeutic option for long-term survival.
Fierce Pharma
NOVEMBER 19, 2024
Two months after Roche scored FDA approval for its subcutaneous ve | Two months after Roche scored FDA approval for its subcutaneous version of PD-LI inhibitor Tecentriq, Merck has achieved a key milestone in lining up its checkpoint inhibitor Keytruda to follow suit. On Tuesday, the company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating non-inferiority to the immunotherapy’s intravenous version.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
NOVEMBER 18, 2024
Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. | Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring.
STAT
NOVEMBER 18, 2024
The genetic sequence of the H5N1 bird flu virus that infected a teenager in British Columbia shows that the virus had undergone mutational changes that would make it easier for that version of H5N1 to infect people, scientists who have studied the data say. There’s currently no evidence the teenager, who remains in critical condition in hospital, infected anyone else.
Pharmacy Times
NOVEMBER 16, 2024
This is the first trial that tested the effect of any medication on major heart failure outcomes in patients with HFpEF and obesity, according to investigators.
Fierce Pharma
NOVEMBER 18, 2024
Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the boat as much as feared for the biopharma industry.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
NOVEMBER 15, 2024
A conversation with Trent Thiede, PharmD, MBA, president of PAAS National, at NCPA 2024.
Fierce Healthcare
NOVEMBER 19, 2024
The FDA will hold its first Digital Health Advisory Committee (DHAC) meeting to discuss how the agency should review medical devices that rely on generative AI, like chatbots. | The FDA seeks advice on regulatory challenges it has identified for generative AI used in medical devices, which include uncertainty about the foundation model, hallucinations and the ability to define intended use.
STAT
NOVEMBER 18, 2024
If he can make it past the Senate, Robert F. Kennedy Jr. will be the next secretary of Health and Human Services. Since the position was created, each secretary has had significant experience in public health, health care administration, or related government work. None has listed “spreading vaccine misinformation” as their primary health care experience.
Pharmacy Times
NOVEMBER 14, 2024
The 2024 American Heart Association and American Stroke Association stroke prevention guidelines recommend glucagon-like peptide-1 receptor agonists to reduce the risk of stroke in individuals with diabetes and high cardiovascular risk.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
NOVEMBER 20, 2024
As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety findings” linked to the British drugmaker’s bleeding reversal agent.
Drug Topics
NOVEMBER 15, 2024
After shared decision making with their community pharmacist, patients were more likely to receive an RSV vaccine.
Fierce Healthcare
NOVEMBER 13, 2024
Primary care player Forward is abruptly shutting down its operations, closing its locations and canceling scheduled visits, the company publicly announced Wednesday. | Primary care player Forward is abruptly shutting down its operations, closing its locations and canceling scheduled visits, the company publicly announced Wednesday.
STAT
NOVEMBER 19, 2024
Robert F. Kennedy Jr. took leave as chairman of Children’s Health Defense, a nonprofit known for spreading doubt about vaccines, to run for president last year. But he is still fighting in court alongside the group, putting him in an unusual position for someone nominated as Secretary of Health and Human Services. If confirmed by the Senate, Kennedy will have power to guide the agencies he oversees toward his priorities.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
NOVEMBER 18, 2024
Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.
Fierce Pharma
NOVEMBER 18, 2024
In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor agonist lorcaserin. | Eisai has terminated a phase 3 study of lorcaserin as a potential adjunct treatment for patients with Dravet syndrome, a rare form of epilepsy that starts in infancy. The company is also shutting down an extended access program in which patients were able to access the medication off-label.
pharmaphorum
NOVEMBER 18, 2024
Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company.A report in Spanish newspaper El Confidencial suggests that Brookfield is preparing to make a bid to take a 65% controlling stake in the drugmaker for €10.50 per share, worth around €7 billion ($7.4 billion).
Fierce Healthcare
NOVEMBER 14, 2024
Amazon One Medical is rolling out a new service to provide Prime members access to clinical treatments for common health and lifestyle conditions like men's hair loss and anti-aging skin care. | Amazon One Medical is rolling out a new service to provide Prime members access to clinical treatments for common health and lifestyle conditions like men's hair loss and anti-aging skin care.
STAT
NOVEMBER 18, 2024
Nothing brought Olivia more joy than when her daughter and grandchild visited her group home in Brooklyn in the early 2000s. Each hug and shared laugh lit up her face with pride like any mother’s, grounded in love, family, and connection. Olivia’s story should not be remarkable, but history almost denied her the chance to experience her family.
Pharmacy Times
NOVEMBER 14, 2024
The label includes postmarking reports showing rare instances of pulmonary aspiration for patients undergoing procedures that require general anesthesia or deep sedation.
Fierce Pharma
NOVEMBER 19, 2024
Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for Enhertu, the trio’s best efforts—and even the intervention of the U.K.’s | Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for Enhertu, the trio’s best efforts—and even the intervention of the U.K.’s new health secretary—have failed to yield a solution.
pharmaphorum
NOVEMBER 14, 2024
There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn't left behind. Its solution is a licensing deal with Chinese biotech LaNova Medicines for LM-299, which consists of an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies.
Fierce Healthcare
NOVEMBER 13, 2024
Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out drug discounts to hospitals. | Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out drug discounts to hospitals. J&J is suing the Health Resources and Services Administration for blocking the implementation of its new 340B rebate model.
STAT
NOVEMBER 16, 2024
California has detected the country’s first case of a new mpox strain that is spreading from person to person. The infected individual had recently traveled from Eastern Africa, where multiple countries are battling transmission of this virus. The individual was treated in a health facility in San Mateo County and is in isolation at home, the California Department of Public Health announced in a statement released Saturday.
Pharmacy Times
NOVEMBER 13, 2024
There has never been such widespread and popularized use of compounded products due to shortages. Will consumers rise up with pitchforks if the party is shut down?
Fierce Pharma
NOVEMBER 13, 2024
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term. | As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in acquiring external products with the potential to launch in the near term, according to a new loss of exclusivity report from Leerink Partners.
pharmaphorum
NOVEMBER 18, 2024
Shortly after a disappointing trial readout for Syndax's menin inhibitor Revuforj in one form of leukaemia, the company has claimed FDA approval in another
Fierce Healthcare
NOVEMBER 19, 2024
Below is a roundup of payer-centric news headlines you may have missed during the month of November 2024. | In this month's payer roundup, a man was charged with insider trading for purchasing Oak Street Health stock before CVS made public the acquisition, the DOJ is honing in on pharmacy benefit managers and OIG found Medicare improperly paid acute-care hospitals by $190 million.
STAT
NOVEMBER 15, 2024
As the saying goes, you are what you eat. And, unfortunately, the food we eat is only solidifying America’s tragic title: We have the lowest life expectancy among large high-income countries. The U.S. Food and Drug Administration is taking a number of steps to help people in the U.S. build healthy diets — including with respect to ultra-processed foods — and the food industry and research community should, too.
Expert insights. Personalized for you.
131 
Let's personalize your content